SCHEMBL10168096

SCHEMBL10168096

CC(C)c1ncc(-c2ccccc2)o1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.53
TSHR P16473 1/20 0.53
CASP1 P29466 1/20 0.53
NOTUM Q6P988 1/20 0.49
KDR P35968 7/20 0.47
FLT1 P17948 6/20 0.47
FLT4 P35916 6/20 0.47
RAB9A P51151 4/20 0.46
NPC1 O15118 3/20 0.46
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 2/20 0.46
HPGD P15428 2/20 0.46
HSD17B10 Q99714 2/20 0.46
MEN1 O00255 1/20 0.46
MITF O75030 1/20 0.46
KMT2A Q03164 1/20 0.46
ATM Q13315 1/20 0.45
CREBBP Q92793 1/20 0.42
VCP P55072 1/20 0.41
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11666531 0.85 ALOX15 (0.50) ALOX15TSHRCASP1NOTUMKDR
SCHEMBL11965500 0.83 NPC1 (0.51) ALOX15TSHRCASP1KDRFLT1
SCHEMBL12920037 0.83 KDM4E (0.51) ALOX15TSHRCASP1RAB9ANPC1
SCHEMBL12920039 0.82 ALDH1A1 (0.53) RAB9ANPC1KDM4EALDH1A1HPGD
SCHEMBL12973918 0.82 NOTUM (0.51) ALOX15TSHRCASP1NOTUMKDR
SCHEMBL823595 0.81 NPC1 (0.45) ALOX15TSHRCASP1KDRFLT1
SCHEMBL12545491 0.81 NOTUM (0.51) ALOX15TSHRCASP1NOTUMKDM4E
SCHEMBL22142966 0.81 FLT1 (0.47) TSHRNOTUMKDRFLT1FLT4
SCHEMBL9671056 0.81 NOTUM (0.46) ALOX15TSHRCASP1NOTUMKDR
SCHEMBL27216984 0.81 ALOX15 (0.53) ALOX15TSHRCASP1NOTUMKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4584259-A1 CK1ALPHA AND DUAL CK1ALPHA / GSPT1 DEGRADING COMPOUNDS Innovo Therapeutics, Inc. (US) 2025-07-16 EP disclosed
US-20240158370-A1 CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS INNOVO THERAPEUTICS, INC. 2024-05-16 US disclosed
WO-2024054832-A1 CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS INNOVO THERAPEUTICS, INC. (US) 2024-03-14 WO disclosed
US-20230158025-A1 GALACTOKINASE INHIBITORS NATIONAL INSTITUTES OF HEALTH 2023-05-25 US disclosed
US-20230158025-A1 GALACTOKINASE INHIBITORS NATIONAL INSTITUTES OF HEALTH 2023-05-25 US disclosed
US-11597727-B2 Inhibitors of integrin alpha 2 beta 1 and methods of use THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-03-07 US disclosed
EP-3684357-B1 HETEROARYL ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS MERCK SHARP & DOHME LLC (US) 2022-12-28 EP disclosed
US-11352329-B2 HIV protease inhibitors GILEAD SCIENCES, INC. (US) 2022-06-07 US disclosed
EP-3967682-A1 BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF Genfleet Therapeutics (Shanghai) Inc. (CN) 2022-03-16 EP disclosed
US-20210387986-A1 INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-12-16 US disclosed
US-20110135650-A1 MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2011-06-09 US disclosed
US-20110059958-A1 MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2011-03-10 US disclosed
US-7871982-B2 Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient MEIJI SEIKA KAISHA, LTD. (JP) 2011-01-18 US disclosed
US-7652023-B2 Heterocyclic CETP inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2010-01-26 US disclosed
US-7652023-B2 Heterocyclic CETP inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2010-01-26 US disclosed
US-20100004295-A1 Hydrazine amide derivative SHIONOGI & CO., LTD. 2010-01-07 US disclosed
US-20090156512-A1 potent activity against resistant pneumococci MEIJI SEIKA KAISHA, LTD. (JP) 2009-06-18 US disclosed
US-7312209-B2 Acridone inhibitors of IMPDH enzyme BRISTOL-MYERS SQUIBB COMPANY (US) 2007-12-25 US disclosed
US-20070135467-A1 HETEROCYCLIC CETP INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2007-06-14 US disclosed
US-20070135467-A1 HETEROCYCLIC CETP INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2007-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110135650-A1 MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS SERPINC1, F9, F8 ALOX15 1221/4885TSHR 2827/4885CASP1 1155/4885
US-11597727-B2 Inhibitors of integrin alpha 2 beta 1 and methods of use ITGB1, ITGB2, ITGA2 ALOX15 3913/4885TSHR 2466/4885CASP1 2189/4885
US-20210387986-A1 INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE ITGB1, ITGB2, ITGA2 ALOX15 3913/4885TSHR 2466/4885CASP1 2189/4885
US-11352329-B2 HIV protease inhibitors PRSS1, SERPINB1, FURIN ALOX15 2747/4885TSHR 4797/4885CASP1 181/4885
US-20070135467-A1 HETEROCYCLIC CETP INHIBITORS CETP, CES1, NPC1 ALOX15 1584/4885TSHR 2250/4885CASP1 1160/4885
US-20240158370-A1 CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS CKS1B, CKS2, MARK1 ALOX15 3260/4885TSHR 4555/4885CASP1 250/4885
US-20230158025-A1 GALACTOKINASE INHIBITORS GALK1, GCK, GCKR ALOX15 2884/4885TSHR 1938/4885CASP1 2374/4885
US-20090156512-A1 potent activity against resistant pneumococci H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NAT1, NPM1 ALOX15 2251/4885TSHR 1003/4885CASP1 212/4885
US-20100004295-A1 Hydrazine amide derivative NPY5R, NPY1R, NPY2R ALOX15 861/4885TSHR 48/4885CASP1 4290/4885
US-20110059958-A1 MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS SERPINC1, F9, F8 ALOX15 1221/4885TSHR 2827/4885CASP1 1155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.